ARISE II 颅内动脉粥样硬化性疾病管理共识
本共识由ARISE II圆桌会议制定,强调颅内动脉粥样硬化性疾病(ICAD)患者应重视生活方式干预与药物治疗,药物治疗失败者可考虑血管内治疗,缺乏血流动力学不足证据者不推荐开放手术,并指出抗栓疗程、CYP2C19基因型影响、新型器械需求及急性期支架术前抗栓方案标准化等知识空白。
要点
- ICAD患者应重视生活方式干预与药物治疗。
- 药物治疗失败者可考虑血管内治疗。
- 缺乏血流动力学不足证据者不推荐开放手术。
核心结论
- 共识强调ICAD患者应重视生活方式干预与药物治疗,药物治疗失败者可考虑血管内治疗,缺乏血流动力学不足证据者不推荐开放手术。
研究设计与样本
- ARISE II(Roundtable Discussion With Industry and Stroke Experts)圆桌会议共识。
主要发现
- 共识指出抗栓治疗最佳疗程、CYP2C19基因型对药物治疗的影响、新型器械需求及急性期支架术前抗栓方案标准化等方面存在知识空白。
- 光学相干断层扫描(OCT)在ICAD诊断中的作用需更多临床数据方能确定。
关键数值与推荐
- 药物治疗失败者可考虑血管内治疗。
- 缺乏血流动力学不足证据者不推荐开放手术。
临床怎么用
- ICAD患者应重视生活方式干预与药物治疗。
- 药物治疗失败者可考虑血管内治疗。
- 缺乏血流动力学不足证据者不推荐开放手术。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intracranial atherosclerotic disease (ICAD) is one of the leading causes of ischemic stroke worldwide. Despite advances in its diagnosis and management, there is no clear consensus on best practices to manage ICAD. This report summarizes the ARISE II (Roundtable Discussion With Industry and Stroke Experts) consensus in treating ICAD. The consensus underscored the importance of lifestyle modification and medical management in patients with ICAD. Patients who fail medical management are candidates for endovascular treatment. Open surgery is not recommended in patients who lack demonstrated hemodynamic insufficiency. The consensus also identified gaps in knowledge about the optimal duration of antithrombotics, the effect of the CYP2C19 genotype on medical management, the need for newer devices, and the standardization of antithrombotic protocols before stenting in an acute setting. Optical coherence tomography requires additional clinical data before defining its role in the diagnosis of ICAD.
引用
- Tjoumakaris SI, Roy JM, Amin-Hanjani S, et al. ARISE II Consensus on the Management of Intracranial Atherosclerotic Disease. Stroke. 2025. PMID: 40408521. doi:10.1161/STROKEAHA.124.050336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。